NDC 67046-082 Bupropion Hydrochloride

View Dosage, Usage, Ingredients, Routes, UNII

Product Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.
NDC Product Code:
67046-082
Proprietary Name:
Bupropion Hydrochloride
Product Type: [3]
INACTIVATED PRODUCT and EXCLUDED the from NDC Directory
Labeler Name: [5]
Contract Pharmacy Services-pa
Labeler Code:
67046
Start Marketing Date: [9]
09-28-2017
Listing Expiration Date: [11]
12-31-2019
Exclude Flag: [12]
I
Code Navigator:

Product Characteristics

Color(s):
WHITE (C48325 - WHITE TO OFF-WHITE)
Shape:
ROUND (C48348)
Size(s):
7 MM
Imprint(s):
A101
Score:
1

Product Packages

NDC Code 67046-082-07

Package Description: 7 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-14

Package Description: 14 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-15

Package Description: 15 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-20

Package Description: 20 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-21

Package Description: 21 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-28

Package Description: 28 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-30

Package Description: 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

NDC Code 67046-082-60

Package Description: 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BLISTER PACK

Product Details

What is NDC 67046-082?

The NDC code 67046-082 is assigned by the FDA to the product Bupropion Hydrochloride which is product labeled by Contract Pharmacy Services-pa. The product's dosage form is . The product is distributed in 8 packages with assigned NDC codes 67046-082-07 7 tablet, film coated, extended release in 1 blister pack , 67046-082-14 14 tablet, film coated, extended release in 1 blister pack , 67046-082-15 15 tablet, film coated, extended release in 1 blister pack , 67046-082-20 20 tablet, film coated, extended release in 1 blister pack , 67046-082-21 21 tablet, film coated, extended release in 1 blister pack , 67046-082-28 28 tablet, film coated, extended release in 1 blister pack , 67046-082-30 30 tablet, film coated, extended release in 1 blister pack , 67046-082-60 60 tablet, film coated, extended release in 1 blister pack . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information and RxNorm crosswalk.

What are the uses for Bupropion Hydrochloride?

Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL) [see Warnings and Precautions ( 5.3) ] .Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions ( 5.3) and Drug Interactions ( 7.3) ]. The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) is contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated [see Dosage and Administration ( 2.9), Warnings and Precautions ( 5.4) and Drug Interactions ( 7.6) ]. Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson Syndrome have been reported [see Warnings and Precautions ( 5.8) ].

Which are Bupropion Hydrochloride UNII Codes?

The UNII codes for the active ingredients in this product are:

Which are Bupropion Hydrochloride Inactive Ingredients UNII Codes?

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:

What is the NDC to RxNorm Crosswalk for Bupropion Hydrochloride?

RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 993541 - buPROPion HCl 150 MG 24HR Extended Release Oral Tablet
  • RxCUI: 993541 - 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet
  • RxCUI: 993541 - bupropion HCl XL 150 MG 24 HR Extended Release Oral Tablet

* Please review the disclaimer below.

Product Footnotes

[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.

[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.

[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.

[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".